Allen R. Chen
Experienced in Neuroepithelioma

Dr. Allen R. Chen

Oncology | Pediatrics
Johns Hopkins Medicine
Johns Hopkins Children's Center
1800 Orleans Street, Bloomberg 11N, Bloomberg 11N, 
Baltimore, MD 

Experienced in Neuroepithelioma
Johns Hopkins Medicine
Johns Hopkins Children's Center
1800 Orleans Street, Bloomberg 11N, Bloomberg 11N, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

"Chen's primary area of research focuses on bone marrow transplantation (BMT), a highly complex and specialized aspect of pediatric oncology that, in recent years, has become an accepted form of therapy for an increasingly broad range of cancers. In addition to the myriad ways BMT is currently being utilized at Hopkins, Chen is working to refine novel approaches to the therapy and apply them to some of the toughest cases. ""One hypothesis is that, in patients receiving a transplant using their own stored stem cells, we can induce an immunologic response from their own cells that mimics the graft received from a healthy donor,"" Chen says. ""We're also excited about the ability to foster immune tolerance when the only available healthy donors aren't perfect matches for the patient."" In a quest to solve some of the rarest and most troubling treatment challenges facing pediatric oncology, Chen and fellow pediatric oncologists at Hopkins have joined forces with others around North America in the Pediatric Blood and Marrow Transplant Consortium. ""We're trying to develop multi-institutional studies to improve the effectiveness of BMT for cancer. The study we're working on now will help us to understand why some patients relapse in spite of BMT for acute myeloid leukemia,"" says Chen, who chairs the Oncology Strategy Group of this consortium. Chen also immerses himself in several Hopkins-based initiatives. Recently, he was named Chair of the Oncology Clinical Research Review Committee, a group mandated to oversee all patient-oriented research in the comprehensive cancer center to ensure it meets the center's standards of scientific merit and priority. He also chairs the Performance Improvement Committee. This multi-disciplinary group consists of physicians, nurses, and pharmacists who examine practical ways to reduce errors and improve patient outcomes. The committee recently joined forces with Hopkins' information technology professionals to apply a computerized order entry system—even to complex treatment protocols like chemotherapy. ""We've seen an amazing improvement; a number of potential medication errors decreased dramatically,"" Chen says. Currently, the committee is analyzing ways to reduce bloodstream infections in pediatric patients, which can create potentially life-threatening complications. Despite the hectic pace of Chen's professional life, he has managed to find a way to leave behind the stress of his job and bond with his own children. He and his sons began taking Kung Fu classes when his older son began middle school. He's since grown up and left for college, but Chen continues the practice as both a student and a teacher. Regardless of where Chen is, he's never too far removed from the challenges that await him at work. ""Sometimes, in the wee hours of the morning, I suddenly realize why a complication has occurred,"" he says.".

Dr. Chen is rated as an Experienced provider by MediFind in the treatment of Neuroepithelioma. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Ganglioneuroblastoma, Leukemia, and Neuroblastoma.

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 4 clinical trials in the study of Neuroepithelioma.

Graduate Institution
Johns Hopkins Bloomberg School Of Public Health, MHS, 2002
Residency
University of Washington Medical Center, Pediatrics, 1989
Specialties
Oncology
Pediatrics
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Pediatrics
Fellowships
University of Washington Medical Center, Pediatric Hematology-Oncology, 1992
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
View 3 Less Insurance Carriers -

Locations

Johns Hopkins Children's Center
1800 Orleans Street, Bloomberg 11N, Bloomberg 11N, Baltimore, MD 21287
Call: 410-955-8751

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Other
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Dinutuximab, Irinotecan Hydrochloride, Sargramostim, Temozolomide, Temsirolimus
Study Phase: Phase 2
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
Enrollment Status: Completed
Publish Date: June 22, 2021
Intervention Type: Procedure, Other
Study Phase: Phase 3
View 6 Less Clinical Trials

57 Total Publications

Acceptability of pictographs as a novel patient identifier to improve patient safety in the neonatal intensive care unit.
Acceptability of pictographs as a novel patient identifier to improve patient safety in the neonatal intensive care unit.
Journal: AMIA ... Annual Symposium proceedings. AMIA Symposium
Published: May 26, 2025
View All 57 Publications
Similar Doctors
Matthias Holdhoff
Distinguished in Neuroepithelioma
Dr. Matthias Holdhoff
Oncology
Distinguished in Neuroepithelioma
Dr. Matthias Holdhoff
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (1.2 miles away)
410-955-8964
Languages Spoken:
English, German
See accepted insurances
Offers Telehealth

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Elite provider by MediFind in the treatment of Neuroepithelioma. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Distinguished in Neuroepithelioma
Dr. Stuart Grossman
Oncology
Distinguished in Neuroepithelioma
Dr. Stuart Grossman
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, 
Baltimore, MD 
 (1.2 miles away)
410-955-8964
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stuart Grossman, M.D., is a professor of oncology at the Johns Hopkins Kimmel Cancer Center. He has served as Principal Investigator and Director of the Central Operations office of the National Cancer Institute-funded phase I/II brain tumor consortia (New Approaches to Brain Tumor Therapy CNS Consortium and the Adult Brain Tumor Consortium) for the past 22 years. He has led many phase I, II, and III institutional and cooperative group translational and clinical brain cancer research projects. Dr. Grossman's expertise is in brain cancers, translational and clinical research, and directing large, multicenter, multidisciplinary clinical trial groups and training programs. Dr. Grossman was an intern and resident at Strong Memorial Hospital in Rochester, NY, and a fellow at the Johns Hopkins University School of Medicine. He received his M.D. from the University of Rochester. Dr. Grossman is rated as an Elite provider by MediFind in the treatment of Neuroepithelioma. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

Distinguished in Neuroepithelioma
Dr. Adam L. Cohen
Oncology
Distinguished in Neuroepithelioma
Dr. Adam L. Cohen
Oncology

Inova Health Care Services

4320 Seminary Rd, 
Alexandria, VA 
 (42.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Cohen is an Oncologist in Alexandria, Virginia. Dr. Cohen is rated as a Distinguished provider by MediFind in the treatment of Neuroepithelioma. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Glioblastoma, Atypical Teratoid Rhabdoid Tumor (ATRT), Bone Marrow Aspiration, and Liver Embolization. Dr. Cohen is currently accepting new patients.

VIEW MORE NEUROEPITHELIOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chen's expertise for a condition
ConditionClose
        • Experienced
        • Acute Lymphoblastic Leukemia (ALL)
          Dr. Chen is
          Experienced
          . Learn about Acute Lymphoblastic Leukemia (ALL).
          See more Acute Lymphoblastic Leukemia (ALL) experts
        • Childhood Acute Myeloid Leukemia
          Dr. Chen is
          Experienced
          . Learn about Childhood Acute Myeloid Leukemia.
          See more Childhood Acute Myeloid Leukemia experts
        • Embryonal Tumor with Multilayered Rosettes
          Dr. Chen is
          Experienced
          . Learn about Embryonal Tumor with Multilayered Rosettes.
          See more Embryonal Tumor with Multilayered Rosettes experts
        • Ganglioneuroblastoma
          Dr. Chen is
          Experienced
          . Learn about Ganglioneuroblastoma.
          See more Ganglioneuroblastoma experts
        • Gliomatosis Cerebri
          Dr. Chen is
          Experienced
          . Learn about Gliomatosis Cerebri.
          See more Gliomatosis Cerebri experts
        • Hodgkin Lymphoma
          Dr. Chen is
          Experienced
          . Learn about Hodgkin Lymphoma.
          See more Hodgkin Lymphoma experts
        View All 9 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile
        For Patients
        • Our Story
        • How MediFind Works
        • Conditions A-Z
        • Doctor Directory
        • Symptoms Directory
        • Procedures Directory
        • Treatment Directory
        • Drug Directory
        • Infusion Center Finder
        • FAQ
        • Contact Us
        For Providers and Practices
        • Claim Your Profile
        • Newsroom
        Business Solutions
        • Provider
        • Network Solutions
        Additional Resources
        • Consumer Health Data Privacy Policy
        • Privacy Policy
        • Terms of Use
        • Advertising Policy
        • Content Policy
        Subscribe to our newsletter

        Sign up to stay informed about MediFind and get wellness sent your way.

        Close

          By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

          Bullet PinMediFind
          Follow us on
          This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
          © 2026 All Rights Reserved

          Request an Appointment

          If you are experiencing a medical emergency, call 9-1-1.

          MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

          Patient Details

          This information is for the patient who will be seen at the appointment.

            Close

            Returning patient? Use your address on file with the provider.

            Insurance Details

            Please provide information of the primary insurance holder as the practice may require this information to schedule.

            Insurance Provider *
            Insurance ProviderClose

            Appointments Details

            Let’s get more information about your appointment.

                    0 / 1000
                    0 / 1000
                    By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.